VTYX — Ventyx Biosciences Income Statement
0.000.00%
Last trade - 00:00- $103.18m
- -$114.14m
- 32
- 50
- 43
- 36
Annual income statement for Ventyx Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 7.05 | 67.1 | 113 | 208 | 148 |
| Operating Profit | -7.05 | -67.1 | -113 | -208 | -148 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -28.2 | -83.7 | -108 | -193 | -135 |
| Net Income After Taxes | -28.2 | -83.7 | -108 | -193 | -135 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -28.2 | -83.7 | -108 | -193 | -135 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28.2 | -85.3 | -108 | -193 | -135 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.576 | -1.69 | -2.07 | -3.29 | -1.97 |
| Dividends per Share |